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Abstract
Introduction To use screening cardiac troponin (cTn)
measurements and electrocardiograms (ECGs) to determine
the incidence of elevated cTn and of myocardial infarction (MI)
in patients admitted to the intensive care unit (ICU), and to
assess whether these findings influence prognosis. This is a
prospective screening study.
Materials and methods We enrolled consecutive patients
admitted to a general medical-surgical ICU over two months. All
patients underwent systematic screening with cTn
measurements and ECGs on ICU admission, then daily for the
first week in ICU, alternate days for up to one month and weekly
thereafter until ICU death or discharge, for a maximum of two
months. Patients without these investigations ordered during
routine clinical care underwent screening for study purposes but
these results were unavailable to the ICU team. After the study,
all ECGs were interpreted independently in duplicate for
ischaemic changes meeting ESC/ACC criteria supporting a
diagnosis of MI. Patients were classified as having MI (elevated
cTn and ECG evidence supporting diagnosis of MI), elevated
cTn only (no ECG evidence supporting diagnosis of MI), or no
cTn elevation.
Results One hundred and three patients were admitted to the
ICU on 112 occasions. Overall, 37 patients (35.9 per cent) had
an MI, 15 patients (14.6 per cent) had an elevated cTn only and
51 patients (49.5 per cent) had no cTn elevation. Patients with
MI had longer duration of mechanical ventilation (p < 0.0001),
longer ICU stay (p = 0.001), higher ICU mortality (p < 0.0001)
and higher hospital mortality (p < 0.0001) compared with those
with no cTn elevation. Patients with elevated cTn had higher
hospital mortality (p = 0.001) than patients without cTn
elevation. Elevated cTn was associated with increased hospital
mortality (odds ratio 27.3, 95 per cent CI 1.7 – 449.4), after
adjusting for APACHE II score, MI and advanced life support.
The ICU team diagnosed 18 patients (17.5 per cent) as having
MI on clinical grounds; four of these patients did not have MI by
adjudication. Thus, screening detected an additional 23 MIs not
diagnosed in practice, reflecting 62.2 per cent of MIs ultimately
diagnosed. Patients with MI diagnosed by the ICU team had
similar outcomes to patients with MI detected by screening
alone.
Conclusion Systematic screening detected elevated cTn
measurements and MI in more patients than were found in
routine practice. Elevated cTn was an independent predictor of
hospital mortality. Further research is needed to evaluate
whether screening and subsequent treatment of these patients
reduces mortality.
Introduction
Diagnosing myocardial infarction in critically ill patients is chal-
lenging [1]. Ischaemic chest pain is uncommon due to analge-
sic use and communication of ischaemic symptoms – when
they occur – is hampered, since these patients are frequently
endotracheally intubated, sedated or comatose. The second
challenge in MI diagnosis is that cTn levels are typically only
measured in critically ill patients with known coronary artery
APACHE, Acute Physiology and Chronic Health Evaluation; CI = confidence interval; cTn = cardiac troponin; cTnT = cardiac troponin T; ECG = 
electrocardiogram; ESC/ACC = European Society of Cardiology/American College of Cardiology; ICU = intensive care unit; IQR = interquartile 
range; MI = myocardial infarction; NSTEMI = non-ST elevation myocardial infarction; OR = odds ratio; STEMI = ST elevation myocardial infarction.Critical Care    Vol 12 No 2    Lim et al.
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disease, or when MI is considered as an explanation for
hypotension or arrhythmia. Thus, it is possible that many ele-
vated cTn levels are never identified and as a result, that the
diagnosis of MI in the intensive care unit (ICU) is frequently
missed [2]. Furthermore, interpretation of an elevated cTn level
in the ICU is challenging because conditions other than MI
which cause cTn elevation [3,4] (such as pulmonary embo-
lism) occur in critically ill patients [5]. For this reason, diagno-
sis of MI requires criteria in addition to elevated cTn levels
such as electrocardiogram (ECG) evidence of myocardial
ischaemia [6].
In a meta-analysis of 23 studies involving 4,492 critically ill
patients, elevated cTn was associated with an adjusted odds
ratio (OR) for death of 2.5 (95 per cent confidence interval [CI]
1.9–3.4) and an increased mean length of ICU stay of three
days (95% CI 0.98–5.05) [7]. This suggests that an elevated
cTn measurement in the ICU setting has prognostic relevance.
However, many studies in this meta-analysis did not undertake
screening cTn measurements to detect clinically silent MIs.
The objective of this study was to use screening cTn measure-
ments and ECGs to determine the incidence of elevated cTn
and MI in consecutive patients admitted to the ICU, and to
assess whether these findings influence prognosis.
Materials and methods
Overview
We screened all consecutive patients admitted to the ICU at
St. Joseph's Hospital, Hamilton, Ontario, Canada from 2 Janu-
ary 2006 to 1 March 2006. On ICU admission, we collected
patient demographics (age, sex, admitting diagnosis, Acute
Physiology and Chronic Health Evaluation [APACHE] II score)
and baseline data (pre-existing medical conditions, cardiac
risk factors and medications).
All cTn and ECGs ordered by the ICU team were collected.
We obtained screening cTn and ECGs if not ordered by the
ICU team; for these screening tests, we obtained deferred
consent from a family member as soon as possible after ICU
admission. If consent was declined for screening cTn and
ECGs, we retained the data that the ICU team ordered, includ-
ing cTn and ECGs. Our institutional Research Ethics Board
approved this study.
Setting
The ICU at St Joseph's Hospital is a 15-bed, university-affili-
ated medical-surgical ICU. Although the hospital has a coro-
nary care unit for patients with primary cardiac diagnoses or
requiring telemetry, such patients also requiring mechanical
ventilation and those receiving inotropes and/or vasopressors
are admitted to the ICU. The ICU is a closed unit staffed by
intensivists and physicians-in-training.
Study participants
All consecutive patients admitted to the ICU during the recruit-
ment period were enrolled. There were no exclusion criteria.
Screening investigations
Troponin measurements
If the ICU team ordered cardiac troponin T (cTnT) for clinical
purposes, a trained Research Coordinator recorded these val-
ues. If the ICU team did not order cTnT, blood was collected
for measurement of cTnT. cTnT measurement was performed
at ICU admission, then daily for the first week in ICU, followed
by alternate days for up to one month and then weekly there-
after until ICU death or discharge, for a maximum of two
months.
All cTnT assays were run in real-time. The ICU team had
access to the cTnT results that they ordered through the hos-
pital computer laboratory system, as per usual practice. To
ensure that levels drawn for study purposes would not influ-
ence patient management, laboratory personnel entered
screening test results in a password protected computer sys-
tem and results were not accessible to the ICU team.
Blood samples for cTnT measurements were drawn into EDTA
tubes, and plasma for sample analysis obtained following cen-
trifugation of whole blood at 1,500 g for 15 minutes. cTnT was
measured using an electrochemiluminescence immunoassay
(Roche Modular analytics E170 [Elecsys module] immu-
noassay analyser, Roche Diagnostics, Indianapolis, IN). The
analytical sensitivity (lower detection limit) of this assay is 0.01
μg/L. An elevated cTn was defined as values greater than or
equal to 0.04 μg/L, which represents the assay coefficient of
variation of 10 per cent.
Electrocardiography
Any 12-lead ECGs (PageWriter, Hewlett-Packard, Palo Alto,
CA) ordered by the ICU team for clinical purposes were pho-
tocopied by the Research Coordinator. If the ICU team did not
order ECGs, the Research Coordinator performed screening
ECGs on ICU admission, then daily for the first week in ICU,
followed by alternate days for the remainder of the first month
and then weekly thereafter until ICU death or discharge, for a
maximum of two months. To ensure that ECGs done for study
purposes would not influence patient management, screening
ECGs were printed out and immediately placed in the
research chart so the results were not accessible to the ICU
team. These ECGs were not reviewed by research staff until
after the study was complete; they were never made available
to the ICU team.
At study completion, two investigators (IQ, DJC) interpreted
ECGs in duplicate, blinded to each others' assessments and
to all clinical information with the exception of cTn levels. All
ECGs were adjudicated for the presence of ischaemic
changes supporting ESC/ACC criteria for MI [6]. ECGs adju-Available online http://ccforum.com/content/12/2/R36
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dicated as having ischaemic changes consistent with MI were
then further classified as ST or non-ST elevation MI (STEMI or
NSTEMI, respectively). All patient identifiers were removed
from the ECGs prior to interpretation. To replicate clinical
practice, the computer-generated ECG interpretation printed
on the ECGs was not removed. Discrepancies were resolved
by discussion.
Data collection
On ICU admission, we collected patient demographics and
baseline data. Daily, we collected laboratory results, cardiac
medications and anticoagulants, new clinical events and com-
plications that the ICU team detected (development of arrhyth-
mias, pulmonary oedema, non-fatal cardiac arrest and
cardiogenic shock), need for advanced life support (mechani-
cal ventilation, inotropes and/or vasopressors, and haemodial-
ysis) and if ischaemic cardiac symptoms were present. We
also collected information on whether the ICU team made a
diagnosis of MI during the patient's ICU stay.
We prospectively followed all patients throughout their ICU
stay, and recorded their vital status and duration of stay in ICU
and hospital. Data were collected from the patient's medical
chart, the ICU computerised clinical information system, and
the hospital laboratory system. Data were recorded on paper
case report forms and entered into an Excel program for
analysis.
Outcomes
Outcome definitions
We defined an elevated cTn as one or more measurements of
cTnT with values greater than or equal to 0.04 μg/L. We
defined MI as one or more measurements of elevated cTn and
one or more ECGs adjudicated as having ischaemic changes
meeting ESC/ACC criteria supporting a diagnosis of MI; the
elevated cTn and ECG changes had to be contemporaneous
to establish a diagnosis of MI.
Patient classification
We classified patients into three groups: MI (as defined
above); elevated cTn only (one or more measurements of ele-
vated cTn during ICU admission and all ECGs classified as
having no ischemic changes supporting ESC/ACC criteria for
MI); or no cTn elevation.
Statistical analysis
We report continuous data as mean and standard deviation or
median and interquartile range, as appropriate. Binary data are
reported as frequency and percentage values. We compared
continuous variables using the Kruskall-Wallis non-parametric
test and the Mann-Whitney paired test to explore the differ-
ences among groups, and categorical variables using the
Pearson's Chi-square test or Fisher's exact test, when appro-
priate. Due to multiple significance testing, a p value < 0.01
was considered statistically significant. In the multivariable
regression analysis, we adjusted for APACHE II score and
advanced life support (mechanical ventilation, inotropes and/
or vasopressors, and haemodialysis at any time in the ICU), to
examine the association between elevated cTn and MI and
ICU and hospital mortality. A sensitivity analysis was per-
formed whereby inotropes and/or vasopressors were not
included as covariates in the regression analysis, since MI may
result in inotrope and/or vasopressor dependence, which may
attenuate the association between an elevated cTn/MI and
mortality. We express associations using odds ratios (ORs)
and 95 per cent CIs.
Results
Over the two-month study period, there were 112 ICU admis-
sions representing 103 unique patients (nine patients were
admitted twice). We obtained deferred consent for 89
patients (86.4 per cent). No consent was obtained for fourteen
patients (13.6 per cent), and no screening cTn and ECG data
were collected on these patients; however, all data available in
the medical record and any cTn and ECGs that the ICU team
ordered for clinical care were recorded. Nine of these 14
patients either died shortly after ICU admission (due to severe
illness or withdrawal of life support), or had short ICU admis-
sions (such as being admitted for airway protection) and cTn
and ECGs were typically ordered by the ICU team for clinical
care so there were few missed screening tests.
The clinical characteristics of the 103 enrolled patients are
shown in Table 1. Most patients were medical (63.1 per cent)
and the admitting APACHE II diagnoses included: cardiovas-
cular (13.8 per cent), respiratory (21.6 per cent), gastrointes-
tinal (12.3 per cent), neurologic (9.3 per cent), sepsis (13.8
per cent), metabolic (16.9 per cent) and haematologic (12.3
per cent). Only one of the nine patients admitted with a cardi-
ovascular diagnosis had an admission diagnosis of acute MI.
The remaining 36.9 per cent were surgical patients, with 27
(71.1 per cent) undergoing elective surgery and 11 (28.9 per
cent) undergoing emergent surgery.
A total of 37 patients (35.9 per cent) had MI, 15 patients (14.6
per cent) had elevated cTn only (that is isolated cTn elevation),
and 51 patients (49.5 per cent) had no cTn elevation. Of the
37 patients with MI, 34 (91.9 per cent) had NSTEMI, and three
(8.1 per cent) had STEMI. At baseline, patients with MI were
older, more commonly admitted for medical reasons and had
higher APACHE II scores than patients without cTn elevation.
Table 2 shows the morbidity and mortality outcomes of the
patients with MI, elevated cTn only and no cTn elevation.
Patients with MI had longer duration of mechanical ventilation
(median 4 versus 1 day, p < 0.0001), increased duration of
ICU stay (median 5 versus 2 days, p = 0.001), higher ICU mor-
tality (37.8 per cent versus 2.0 per cent, p < 0.0001) and
higher hospital mortality (43.2 per cent versus 2.0 per cent,
p < 0.0001) compared to patients with no cTn elevation.Critical Care    Vol 12 No 2    Lim et al.
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Table 1
Clinical characteristics of enrolled patients
Total MI Elevated cTn only No cTn elevation p value3 p value4
(N = 103) (N = 37) (N = 15) (N = 51)
Age, mean (SD) 64.1 ± 17.5 69.9 ± 14.9 64.3 ± 21.8 59.7 ± 16.9 0.018 - MI vs cTn, p = 0.467
- cTn vs no cTn elevation, p = 0.309
- MI vs no cTn elevation, p = 0.004
Female sex, N (%) 44 (42.7) 16 (43.2) 4 (26.7) 24 (47.1) 0.372 - MI vs cTn, p = 0.352
- cTn vs no cTn elevation, p = 0.236
- MI vs no cTn elevation, p = 0.829
APACHE II score, mean 
(SD)
21.4 ± 10.3 28.2 ± 9.5 22 ± 8.3 16.2 ± 8.3 <0.0001 - MI vs cTn, p = 0.045
- cTn vs no cTn elevation, p = 0.014
- MI vs no cTn elevation p < 0.0001
Medical, N (%) 65 (63) 32 (86.5) 10 (66.7) 23 (45.1) <0.0001 - MI vs cTn, p = 0.129
- cTn vs no cTn Elevation p = 0.240
- MI vs no cTn elevation p < 0.0001
Past medical history,
N (%)
Smoking 28 (27.2) 10 (27.0) 4 (26.7) 14 (27.5) 0.998 - MI vs cTn, p = 1.000
- cTn vs no cTn elevation, p = 1.000
- MI vs no cTn elevation, p = 1.000
Hypertension 54 (52.4) 24 (64.9) 9 (60.0) 21 (41.2) 0.073 - MI vs cTn, p = 0.760
- cTn vs no cTn elevation, p = 0.245
- MI vs no cTn elevation, p = 0.033
Diabetes mellitus1 25 (24.3) 13 (35.1) 4 (26.7) 8 (15.7) 0.107 - MI vs cTn, p = 0.747
- cTn vs no cTn elevation, p = 0.446
- MI vs no cTn elevation, p = 0.044
Hyperlipidemia 17 (16.5) 6 (16.2) 5 (33.3) 6 (11.8) 0.141 - MI vs cTn, p = 0.260
- cTn vs no cTn elevation, p = 0.107
- MI vs no cTn elevation, p = 0.549
Documented coronary 
disease/angina
3 (2.9) 1 (2.7) 1 (6.7) 1 (2.0) 0.632 - MI vs cTn, p = 0.498
- cTn vs no cTn elevation, p = 0.406
- MI vs no cTn elevation, p = 1.000
Prior myocardial infarction 5 (4.9) 4 (10.8) 1 (6.7) 0 (0) 0.062 - MI vs cTn, p = 1.000
- cTn vs no cTn elevation, p = 0.227
- MI vs no cTn elevation, p = 0.028
Congestive heart failure 16 (15.5) 10 (27) 2 (13.3) 4 (7.8) 0.048 - MI vs cTn, p = 0.470
- cTn vs no cTn elevation, p = 0.612
- MI vs no cTn elevation, p = 0.020
Peripheral vascular 
disease
13 (12.6) 7 (18.9) 3 (20.0) 3 (5.9) 0.124 - MI vs cTn, p = 1.000
- cTn vs no cTn elevation, p = 0.125
- MI vs no cTn elevation, p = 0.088
Stroke/transient ischemic 
attack
10 (9.7) 5 (13.5) 3 (20.0) 2 (3.9) 0.112 - MI vs cTn, p = 0.676
- cTn vs no cTn elevation, p = 0.073
- MI vs no cTn elevation, p = 0.126
Baseline life support 
interventions, N (%)
Ventilation
Invasive mechanical 
ventilation
59 (57.3) 27 (73.0) 7 (46.7) 25 (49.0) 0.054 - MI vs cTn, p = 0.108
- cTn vs no cTn elevation, p = 0.100
- MI vs no cTn elevation, p = 0.029
Non-invasive mechanical 
ventilation
4 (3.9) 1 (2.7) 1 (6.7) 2 (3.9) 0.799 - MI vs cTn, p = 0.498
- cTn vs no cTn elevation, p = 0.545
- MI vs no cTn elevation, p = 1.000
Inotropes and 
vasopressors, N (%)Available online http://ccforum.com/content/12/2/R36
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Patients with elevated cTn had higher hospital mortality (26.7
per cent versus 2.0 per cent, p = 0.001) compared with
patients without cTn elevation. There was no difference in hos-
pital stay among the three patient groups (p = 0.124).
We present predictors of ICU and hospital mortality in Table
3. Both elevated cTn and MI were associated with ICU mortal-
ity and hospital mortality in univariable analysis. Elevated cTn
was associated with hospital mortality (OR 27.3, 95 per cent
Epinephrine 3 (2.9) 3 (8.1) 0 (0) 0 (0) 0.064 - MI vs cTn, p = 0.548
- cTn vs no cTn elevation, p = NE
- MI vs no cTn elevation, p = 0.071
Dopamine2 6 (5.8) 5 (13.5) 0 (0) 1 (2.0) 0.043 - MI vs cTn, p = 0.305
- cTn vs no cTn elevation, p = 1.000
- MI vs no cTn elevation, p = 0.079
Norepinephrine 14 (13.6) 9 (24.3) 2 (13.3) 3 (5.9) 0.045 - MI vs cTn, p = 0.477
- cTn vs no cTn elevation, p = 0.318
- MI vs no cTn elevation, p = 0.024
Dobutamine 2 (1.9) 2 (5.4) 0 (0) 0 (0) 0.162 - MI vs cTn, p = 1.000
- cTn vs no cTn elevation, p = NE
- MI vs no cTn elevation, p = 0.174
Phenylephrine 3 (2.9) 3 (8.1) 0 (0) 0 (0) 0.064 - MI vs cTn, p = 0.548
- cTn vs no cTn elevation, p = NE
- MI vs no cTn elevation, p = 0.071
Vasopressin 1 (1.0) 1 (2.7) 0 (0) 0 (0) 0.406 - MI vs cTn, p = 1.000
- cTn vs no cTn elevation, p = NE
- MI vs no cTn elevation, p = 0.420
Hemodialysis, N (%)
Intermittent dialysis 9 (8.7) 6 (16.2) 1 (6.7) 2 (3.9) 0.125 - MI vs cTn, p = 0.658
- cTn vs no cTn elevation, p = 0.545
- MI vs no cTn elevation, p = 0.065
Continuous renal 
replacement therapy
1 (1.0) 1 (2.7) 0 (0) 0 (0) 0.406 - MI vs cTn, p = 1.000
- cTn vs no cTn elevation, p = NE
- MI vs no cTn elevation, p = 0.420
APACHE = Acute Physiology and Chronic Health Evaluation; cTn = cardiac troponin; MI = myocardial infarction; NE = not estimable; 1Managed 
with oral agents and/or insulin; 2>3 μg/kg/min; 3p value indicates a 3-way comparison; 4p value indicates a 2-way comparison.
Table 2
Frequency of morbidity and mortality outcomes
MI (N = 37) Elevated cTn only
(N = 15)
No cTn elevation
(N = 51)
p value1 p value2
Duration of mechanical ventilation, 
median (IQR [days])
4 (0.5–12.5) 2 (0–3) 1 (0–2) <0.0001 - MI vs cTn, p = 0.022
- cTn vs no cTn elevation, p = 0.167
- MI vs no cTn elevation, p < 0.0001
Duration of ICU stay, median
(IQR [days])
5 (2–14) 4 (3–7) 2 (1–4) 0.002 - MI vs cTn, p = 0.336
- cTn vs no cTn elevation, p = 0.026
- MI vs no cTn elevation, p = 0.001
ICU mortality, N (%) 14 (37.8) 1 (6.7) 1 (2.0) <0.0001 - MI vs cTn, p = 0.020
- cTn vs no cTn elevation, p = 0.357
- MI vs no cTn elevation, p < 0.0001
Duration of hospital stay, median
(IQR [days])
15 (4–37) 12 (6–12) 8 (4–19) 0.124 - MI vs cTn, p = 0.785
- cTn vs no cTn elevation, p = 0.175
- MI vs no cTn elevation, p = 0.062
Hospital mortality, N (%) 16 (43.2) 4 (26.7) 1 (2.0) <0.0001 - MI vs cTn, p = 0.139
- cTn vs no cTn elevation, p = 0.001
- MI vs no cTn elevation, p < 0.0001
cTn = cardiac troponin; ICU = intensive care unit; IQR = interquartile range; MI = myocardial infarction; 1p value indicates a three-way 
comparison; 2p value indicates a two-way comparison.
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CI 1.7–449.4), but not ICU mortality in multivariable analysis
after adjusting for illness severity and need for advanced life
support. MI was not significantly associated with ICU and hos-
pital mortality in multivariable analysis. Similar results were
observed in the sensitivity analysis where inotrope and/or
vasopressor use was omitted from the regression; after adjust-
ing for illness severity and need for mechanical ventilation and
haemodialysis, elevated cTn was significantly associated with
hospital mortality (OR 19.7, 95 per cent CI 1.5–260.4)
In terms of complications, most patients did not develop
arrhythmias, pulmonary oedema, non-fatal cardiac arrest or
cardiogenic shock (Table 4). However, almost twice as many
patients with MI developed pulmonary oedema compared with
those with no cTn elevation (37.8 per cent versus 11.8 per
cent, respectively, p = 0.005).
We report the use of antithrombotic agents and cardiac med-
ications in Table 5. Patients with MI were more likely to receive
antiplatelet medications, therapeutic dose heparin and long-
acting nitrates compared to patients without cTn elevation.
Based on clinical presentation, 18 patients (17.5 per cent)
were diagnosed by the ICU team as having MI, but on adjudi-
cation, four of these patients did not meet criteria for MI (three
patients did not have cTn elevation and the ECG of one patient
was not adjudicated as meeting ESC/ACC criteria for MI). Of
these 14 patients with MI detected clinically, 12 were NSTEMI
and two were STEMI. Screening cTn and ECGs therefore
identified 23 patients with MI who were 'missed' by routine
clinical practice (reflecting 62.2 per cent of MIs ultimately
diagnosed). Of these 23 patients with MI detected by screen-
ing, 22 were NSTEMI and one was STEMI. The outcome of
patients with MI diagnosed clinically compared with MIs
detected through screening is shown in Table 6. Of the 18
patients with MI diagnosed clinically by the ICU team, seven
(38.9 per cent) died in the ICU and a further two died while in
hospital (total hospital mortality of nine patients, representing
Table 3
Predictors of ICU and hospital mortality
ICU mortality Hospital mortality
Univariable Multivariable Univariable Multivariable
Predictors OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI)
APACHE II score (10-pt increment) 5.7 (2.6–12.6) 3.9 (1.3–11.8) 4.9 (2.5–9.9) 3.5 (1.2–10.1)
Mechanical ventilation Not estimable1 Not estimable1 17.3 (2.2–134.8) 7.4 (0.7–79.9)
Inotropes or vasopressors 78.2 (9.6–640.9) 23.6 (2.5–219.3) 17.0 (5.3–54.5) 6.3 (1.3–29.3)
Hemodialysis 2.1 (0.6–7.5) 0.3 (0.04–3.3) 1.4 (0.4–4.8) 0.2 (0.02–2.02)
Elevated cTn 20.3 (2.6–160.4) 2.8 (0.1–70.6) 31.3 (4.0–244.4) 27.3 (1.7–449.4)
MI 19.5 (4.1–92.4) 4.1 (0.3–51.9) 9.3 (3.0–28.5) 0.7 (0.1–4.4)
APACHE = Acute Physiology and Chronic Health Evaluation; CI = confidence interval; cTn = cardiac troponin; ICU = intensive care unit; MI = 
myocardial infarction; OR = odds ratio; 1Not estimable because all patients were either ventilated or died or both.
Table 4
Clinical complications
MI, N (%) (N = 37) Elevated cTn,
N (%) (N = 15)
No cTn elevation,
N (%) (N = 51)
p value1 p value2
Arrhythmia requiring treatment 1 (2.7) 0 (0) 1 (1.8) 0.846 - MI vs cTn, p = 1.000
- cTn vs no cTn elevation, p = 1.000
- MI vs no cTn elevation, p = 1.000
Pulmonary oedema 14 (37.8) 3 (20.0) 6 (11.8) 0.015 - MI vs cTn, p = 0.330
- cTn vs no cTn elevation, p = 0.414
- MI vs no cTn elevation, p = 0.005
Non-fatal cardiac arrest 2 (5.4) 0 (0) 0 (0) 0.162 - MI vs cTn, p = 1.000
- cTn vs no cTn elevation, p = NE
- MI vs no cTn elevation, p = 0.174
Cardiogenic shock 2 (5.4) 0 (0) 0 (0) 0.162 - MI vs cTn, p = 1.000
- cTn vs no cTn elevation, p = NE
- MI vs no cTn elevation, p = 0.174
cTn = cardiac troponin; MI = myocardial infarction; NE = not estimable; 1p value indicates a three-way comparison; 2p value indicates a two-way 
comparison; note that two patients had more than one MI, so the totals exceeds 100 per cent.Available online http://ccforum.com/content/12/2/R36
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50 per cent mortality rate); nine patients (50 per cent) with
clinically diagnosed MI were ultimately discharged from hospi-
tal. In comparison, of the 23 patients with MI diagnosed by
screening, eight (34.8 per cent) died in the ICU and there
were no further deaths while in hospital (total hospital mortality
of eight patients, representing a 35 per cent mortality rate); 15
patients (65.2 per cent) with MI diagnosed by screening were
ultimately discharged from hospital. Patients with MI diag-
nosed clinically were similar to patients with MI detected by
screening alone with respect to ICU and hospital length of
stay, and ICU and hospital mortality.
Table 5
Cardiac medications
MI, N (%) (N = 37) Elevated cTn,
N (%) (N = 15)
No cTn elevation,
N (%) (N = 51)
p value1 p value2
Antiplatelet agents 26 (70.3) 7 (46.7) 16 (31.4) 0.001 - MI vs cTn, p = 0.126
- cTn vs no cTn elevation, p = 0.358
- MI vs no cTn elevation, p < 0.0001
Anticoagulant UFH 7 (19.4) 0 (0) 0 (0) 0.001 - MI vs cTn, p = 0.090
- cTn vs no cTn elevation, p = NE
- MI vs no cTn elevation, p = 0.001
Anticoagulant LMWH 3 (8.3) 0 (0) 0 (0) 0.064 - MI vs cTn, p = 0.546
- cTn vs no cTn elevation, p = NE
- MI vs no cTn elevation, p = 0.072
Anticoagulant Warfarin 8 (22.2) 3 (20.0) 4 (8.0) 0.156 - MI vs cTn, p = 1.000
- cTn vs no cTn elevation, p = 0.338
- MI vs no cTn elevation, p = 0.112
Long acting nitrates 19 (51.4) 5 (33.3) 6 (12.0) <0.0001 - MI vs cTn, p = 0.358
- cTn vs no cTn elevation, p = 0.109
- MI vs no cTn elevation, p < 0.0001
Statin 19 (51.4) 7 (46.7) 18 (35.3) 0.306 - MI vs cTn, p = 1.000
- cTn vs no cTn elevation, p = 0.547
- MI vs no cTn elevation, p = 0.189
ACE inhibitors/ARBs 11 (29.7) 5 (33.3) 7 (14.0) 0.123 - MI vs cTn, p = 1.000
- cTn vs no cTn elevation, p = 0.128
- MI vs no cTn elevation, p = 0.108
Beta-blockers 25 (67.6) 5 (33.3) 20 (39.2) 0.014 - MI vs cTn, p = 0.032
- cTn vs no cTn elevation, p = 0.769
- MI vs no cTn elevation, p = 0.010
Calcium channel blocker 13 (35.1) 4 (26.7) 11 (21.6) 0.369 - MI vs cTn, p = 0.747
- cTn vs no cTn elevation, p = 0.731
- MI vs no cTn elevation, p = 0.225
Diuretic 25 (67.6) 9 (60.0) 17 (33.3) 0.004 - MI vs cTn, p = 0.749
- cTn vs no cTn elevation, p = 0.078
- MI vs no cTn elevation, p = 0.002
Digoxin 8 (22.2) 0 (0) 2 (3.9) 0.007 - MI vs cTn, p = 0.087
- cTn vs no cTn elevation, p = 0.594
- MI vs no cTn elevation, p = 0.014
ARBs = angiotensin receptor blockers; cTn = cardiac troponin; IV = intravenous; LMWH = low molecular weight heparin; MI = myocardial 
infarction; NE = not estimable; 1p value indicates a three-way comparison;2p value indicates a two-way comparison.
Table 6
Outcomes of patients with MI diagnosed clinically vs. MI diagnosed by screening
MI diagnosed by ICU team (N = 18) MI diagnosed by screening only (N = 23) p value1
ICU mortality, N (%) 7 (38.9) 8 (34.8) 1.0002
Hospital mortality, N (%) 9 (50) 8 (34.8) 0.3582
ICU length of stay (mean days ± SD) 12.1 ± 16.4 8.5 ± 10.1 0.5803
Mean hospital length of stay (mean days ± SD) 33.8 ± 34.6 23.5 ± 25 0.2873
ICU = intensive care unit; MI = myocardial infarction; SD = standard deviation; 1p value indicates a two-way comparison; 2Chi-Square test; 
3Mann-Whitney test.Critical Care    Vol 12 No 2    Lim et al.
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Discussion
In this observational screening study, 36 per cent of patients
admitted to the ICU met diagnostic criteria for MI and 15 per
cent had isolated cTn elevation during their ICU stay. Patients
with MI had a longer ICU stay and increased hospital mortality
compared with patients without cTn elevation; patients with MI
also had a longer duration of mechanical ventilation and
increased ICU mortality compared with those with and without
cTn elevation. We documented that elevated cTn levels are
associated with hospital mortality, even after adjusting for
other important potential confounders. Patients with MI devel-
oped pulmonary oedema more frequently than those without
MI, and were more likely to receive anti-ischaemic, antiplatelet
and heparin therapy. Use of screening investigations detected
more MIs than clinical diagnosis alone; however, the ICU and
hospital length of stay and ICU and hospital mortality were
similar for patients whose MIs were diagnosed by the ICU
team and by screening.
This study is novel in that we performed both serial screening
cTn measurements and ECG recordings on all patients admit-
ted to the ICU. Screening investigations are relevant in this
population since ICU patients frequently receive analgesic and
sedative agents that can blunt pain and impair consciousness;
moreover, they are commonly intubated and cannot communi-
cate ischaemic symptoms that would typically initiate cardiac
investigations. Thus, MI in the ICU setting is frequently undiag-
nosed. We previously audited the cTn ordering practice in this
ICU without a screening protocol [2]. We found that 81 per
cent of patients admitted to the ICU had at least 1 cTn meas-
urement and 1 ECG; of these patients, 47 per cent had at
least 1 elevated cTn level and 26 per cent met diagnostic cri-
teria for MI by similar adjudication criteria as in the current
study (elevated cTn and ischaemic ECG changes). The higher
frequency of MI in the current study (36 per cent) is likely
attributable to the screening process. In our previous study
documenting cTn elevations noted by the ICU team, we also
found that patients with MI compared with those without had
significantly higher ICU and hospital mortality. Including MI
identified by screening in the current study, we similarly found
that patients with MI had significantly higher mortality in the
ICU and hospital compared to patients without cTn elevation.
Although subgroup analyses were not performed due to the
relatively small number of patients with MI, there is a sugges-
tion that patients at risk for MI more commonly had a history of
hypertension, diabetes mellitus, prior myocardial infarction or
congestive heart failure (Table 1).
Elevated cTn appears to be an adverse prognostic marker
among critically ill patients. We found that elevated cTn was
associated with increased hospital mortality (OR 27.3, 95 per
cent CI 1.7 – 449.4). In a study of thoracic surgery and vascu-
lar surgery ICU patients, limited cTnT and ECG screening was
performed but no difference in mortality rates was found
between patients with and without cTn elevation [8]. In
another study, ICU patients admitted with non-cardiac diag-
noses who had an elevated cTn were found to have a four-fold
higher mortality (22.4 vs. 5.2 per cent, p < 0.018) than
patients without cTn elevation [5]. Among surgical ICU
patients, moderate elevations in cTnI were associated with
increased mortality and longer hospital and ICU length of stay
compared to patients with normal cTn levels [9]. In a meta-
analysis of 23 observational studies of critically ill patients, ele-
vated cTn was associated with an adjusted OR for death of
2.5 (95 per cent CI 1.9–3.4) [7]. In unadjusted analyses with
significant heterogeneity of results, elevated cTn was
associated with an increased mean length of ICU stay of three
days (95 per cent CI 0.98–5.05).
Since cTn is only released from damaged myocardial cells,
elevated levels represent myocardial damage, which can plau-
sibly increase the risk of death regardless of the mechanism. It
is possible that because the aetiology of cTn elevation is vari-
able in critically ill patients, the association with mortality and
other adverse outcomes may also vary, and may be difficult to
detect, thus requiring a larger sample size to estimate the true
consequences of elevated cTn. Another issue influencing
analysis of the impact of elevated cTn levels is that ECG inter-
pretation, often done concurrently in practice, may have only
moderate inter and intra-rater reliability in the ICU setting,
which improves with knowledge of the cTn levels [10].
Recognising critically ill patients who have MI (versus an ele-
vated cTn alone) may be important since these patients may
benefit from antithrombotic and anti-ischaemic medications
that have been shown to benefit non-critically ill patients.
Whether these agents improve the outcome of patients with
cTn elevation alone in the absence of ECG changes is
unknown. Furthermore, the safety of these medications in crit-
ically ill patients with cTn elevation and ECG changes should
be further explored since certain agents used widely in the ICU
(such as beta-agonists) may be incompatible with cardiac
medications (such as beta-blockers).
Strengths of the current study include the use of systematic
screening investigations to examine cTn and ECG abnormali-
ties that were not detected by the ICU team. The diagnosis of
MI was made independently and in duplicate, blinded to the
patient's clinical information. Furthermore, the cTn and ECG
abnormalities documented during screening procedures were
unavailable to the ICU team so they could not influence prac-
tice. We used multivariable analysis to examine the association
between elevated cTn and MI with mortality. Limitations to the
current study include the sample size and relatively small
number of patients in each subgroup. Although we examined
medication use among the subgroups, we cannot make infer-
ences from this cohort study about the effectiveness of these
medications. Lastly, the results of this study may not be appli-
cable to other settings with a different patient case-mix, such
as trauma units.Available online http://ccforum.com/content/12/2/R36
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The mechanism for cTn elevation may differ in critically ill
patients compared with conscious non-ICU patients present-
ing with chest discomfort and cTn elevation, but ultimately
both cases result in myocardial cell necrosis. As per the cur-
rent consensus definition of MI whereby any amount of myo-
cardial necrosis reflecting any degree of cTn elevation can be
considered an infarction [6], we used the term 'myocardial inf-
arction' without implying the possible mechanism. Further
research is needed to better understand mechanisms for cTn
elevations in critically ill patients.
Conclusion
Elevated cTn levels are common in critically ill patients when
assessed by screening, and appear to have an important prog-
nostic association with increased hospital mortality. We found
that approximately one-third of patients also had ischaemic
ECG changes in addition to elevated cTn levels, suggesting
MI. Further research is needed to evaluate whether screening
for MI and subsequent treatment of these patients reduces
mortality.
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